Search

RC88

RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).

Povetacicept

Povetacicept is under investigation in clinical trial NCT05757570 (An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias).

Ovatodiolide

Ovatodiolide is under investigation in clinical trial NCT04220411 (A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD)).

R112

R112 is an investigational compound developed to treat Allergic Rhinitis. It's mechanism of action is to inhibit SYK kinase.

Beta-(1,3)-D glucan

5-methoxy-N,N-dimethyltryptamine

It is found in a wide variety of plant species, and a single psychoactive toad species, the Colorado River toad. … This drug, as well as [dimethyltryptamine] and [bufotenin], have been registered to be used in South America in religious and spiritual rituals.

MEM 1414

MEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of the brain where new memories are formed. … MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials.

(1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide

These are compounds containing an oxepane ring, which is an a seven-member saturated aliphatic heterocycle with one oxygen and six carbon atoms. This drug targets the protein beta-glucosidase A. … (1S,2R,3S,4R,5R)-2,3,4-trihydroxy-N-octyl-6-oxa-8-azabicyclo[3.2.1]octane-8-carbothioamide is a solid. This compound belongs to the oxepanes.

MLN3897

MLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.

CYP-001

These cells have advantage over other MSCs because a large amount can be obtained from a single healthy blood donor, negating the risks from donor-and expansion dependent variability. … CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm.